Fresenius reorganizes its hospital services business
Effective January 1, 2027, Fresenius will integrate the hospital services it provides internally for Helios into Helios Kliniken GmbH. About 1,700 of the more than 4,000 employees of Fresenius Health Services (FHS) will transfer to Helios together with their service companies. Going forward, FHS will focus entirely on external clients, who already account for around two thirds of FHS’s revenue. As a result of this step, Helios will benefit from an even closer collaboration in the hospitals' technical infrastructure going forward. FHS, in turn, will be able to focus entirely on its external business and continue to develop in that area.
Fresenius expands Medical Nutrition Portfolio with new real-food-based1 enteral nutrition concept
NutriChef launches in several European markets and combines real food ingredients1 with the consistency and nutritional completeness of medical nutritionThe launch of NutriChef, the fifth product launch within Fresenius’ Medical Nutrition portfolio in 2026, reflects the company’s commitment to patient-centered innovation-led growth and further strengthens its portfolio in nutritional careNutriChef expands Fresenius’ enteral nutrition offering with a real-food-based concept designed around the needs of patients, caregivers, and healthcare professionalsMedical Nutrition is an attractive healthcare market supported by aging populations, increased demand for homecare, and growing awareness of the role of nutrition in patient careFresenius announced today the launch of NutriChef, a new enteral nutrition option that combines real food ingredients1 such as fruit and vegetables while maintaining the nutritional completeness required for medical nutrition, in Germany, Switzerland, Norway, Netherlands, Denmark, and Sweden. The product is designed to bridge the gap between conventional formula-based tube feeding and the familiarity associated with real meals and home-prepared foods. Available in three nutritionally complete, meal-inspired varieties2, they contain ingredients derived from 21 different plants and more than 75 percent real food ingredients, including water and oils1. The product provides high energy and protein as well as a blend of soluble and insoluble fibers.“For many patients, the challenge is not only getting the nutrition they need. It is adapting to a new reality,” said Sebastien Guery, Executive Vice President Business Unit Medical Nutrition. “NutriChef responds to that need by combining familiar foods into enteral feeding with the safety, consistency and nutritional standards required in medical care. It is also a testament to the innovation-led growth of Fresenius, reflecting our ability to translate evolving patient needs into differentiated innovations and meaningful portfolio expansion.”Developed for patients who require enteral nutrition, the new offering combines familiar food-based ingredients with the reliability and quality standards expected from medical nutrition. It offers patients, caregivers, and healthcare professionals an additional option that brings familiar food concepts into nutritional care.As populations age and more care shifts beyond the hospital into outpatient and homecare settings, nutritional support is becoming increasingly important across healthcare systems. Fresenius continues to see strong long-term demand in Medical Nutrition, supported by demographic trends, growing awareness of disease-related malnutrition, and the need for solutions that fit into patients’ daily lives.As the fifth addition to Fresenius’ Medical Nutrition portfolio introduced in 2026, NutriChef underscores the company’s continued investment in nutritional care across enteral and parenteral nutrition, the company continues to expand access to high-quality medical nutrition while addressing practical challenges faced by patients, caregivers, and healthcare professionals. As part of #FutureFresenius, the company continues to strengthen its portfolio with differentiated solutions that address evolving patient needs. NutriChef is a food for special medical purposes for the dietary management of disease-related malnutrition, to be used under medical supervision. Product availability may vary by market.NutriChef is essentially designed as an adult medical nutrition product, with limited, controlled use in:children >3 years (restricted)adolescents (possible full use only with medical supervision) References1 Fresenius Kabi. NutriChef Ingredient List and Product Specification. Fresenius Kabi; 2026.2 Fresenius Kabi Market Research; Real Food & Tube Feeding Insights Study, 2022.
Fresenius Opens Innovation Center for Medical Nutrition in Bad Homburg
Fresenius today officially opened its new Innovation Center in Bad Homburg, Germany, marking a major milestone in strengthening research, development, and innovation in medical nutrition.
June 02, 2026 · Fresenius Kabi
Brief News
AI assistant enhances access to Investor Relations information
Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
Michael Sen, CEO of Fresenius, emphasized: “In the past financial year, we showed that Fresenius can deliver a strong performance even in an environment where volatility has become the norm.”
#FutureFresenius: REJUVENATE in action – Excellent start to the year - demonstrating continued strength and resilient performance; Guidance reconfirmed
Michael Sen, CEO of Fresenius: "Fresenius made an excellent start to 2026, delivering performance fully in line with our expectations and leading us to reconfirm our full‑year guidance.